HCAF support categories fact sheet
6 April 2021Fact sheetThis fact sheet provides information for participants of the Australian Thalidomide Survivors Support Program about the categories of goods and services which are eligible to be claimed under the Health Care Assistance Fund (HCAF).
Part of a collection: Australian Thalidomide Survivors Support Program resourcesMaking a claim to the HCAF fact sheet
1 April 2021Fact sheetThis factsheet provides information about how participants of the Australian Thalidomide Survivors Support Program can make a claim to the Health Care Assistance Fund (HCAF). The HCAF helps cover out-of-pocket health care expenses incurred as a direct result of thalidomide injuries.
Part of a collection: Australian Thalidomide Survivors Support Program resourcesEAF support categories fact sheet
1 April 2021Fact sheetThis factsheet provides information for participants of the Australian Thalidomide Survivors Support Program about the categories of goods and services which are eligible to be claimed under the Extraordinary Assistance Fund (EAF).
Part of a collection: Australian Thalidomide Survivors Support Program resourcesMaking a claim to the EAF fact sheet
1 April 2021Fact sheetThis factsheet provides information about how participants of the Australian Thalidomide Survivors Support Program can make a claim to the Extraordinary Assistance Fund (EAF). The EAF helps cover the costs of goods and services to assist with activities of daily living.
Part of a collection: Australian Thalidomide Survivors Support Program resourcesThalidomide health practitioner evidence form
1 April 2021Fact sheetThis form is a template for health practitioners to provide evidence to support an eligible thalidomide survivor (patient) to receive support from the Extraordinary Assistance Fund (EAF) or the Health Care Assistance Fund (HCAF).
Part of a collection: Australian Thalidomide Survivors Support Program resources- Tagalog - Tagalog12 March 2021Presentation
Bowel screening can save your life. This video, hosted by the North Western Melbourne Primary Health Network explains in Tagalog, how to do the test when you receive your screening kit in the mail.
Support for Australia’s thalidomide survivors
24 February 2021Government response to inquiryAustralian Government response to the Senate Community Affairs References Committee inquiry into support for Australia’s thalidomide survivors
LSDPEP 8th meeting agenda – 19 February 2021
16 February 2021AgendaLife Saving Drugs Program Expert Panel (LSDPEP) agenda for the 8th meeting on 19 February 2021.
LSDPEP 6th meeting agenda – 25 and 26 June 2020
3 February 2021AgendaLife Saving Drugs Program Expert Panel (LSDPEP) agenda for the 6th meeting on 25 and 26 June 2020.
LSDPEP 7th meeting agenda – 22 and 23 October 2020
3 February 2021AgendaLife Saving Drugs Program Expert Panel (LSDPEP) agenda for the 7th meeting on 22 and 23 October 2020.
LSDPEP 5th meeting agenda – 16 and 17 April 2020
3 February 2021AgendaLife Saving Drugs Program Expert Panel (LSDPEP) agenda for the 5th meeting on 16 and 17 April 2020.
Life Saving Drugs Program – Eliglustat (Cerdelga®) outcome statement
3 February 2021ReportThis document states the outcome of Sanofi-Aventis Australia's application to include eliglustat on the Life Saving Drugs Program.
Life Saving Drugs Program – Cerliponase alfa (Brineura®) outcome statement
3 February 2021ReportThis document states the outcome of BioMarin's application to include cerliponase alfa on the Life Saving Drugs Program.
Life Saving Drugs Program – Asfotase alfa (Strensiq®) outcome statement
3 February 2021ReportThis document states the outcome of Alexion Pharmaceuticals Australasia's application to include asfotase alfa on the Life Saving Drugs Program.
Life Saving Drugs Program – Hereditary tyrosinaemia (type 1) – Initial application
3 February 2021FormTreating physicians use this application form to apply for a patient to access LSDP medication for hereditary tyrosinaemia (type 1) for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Hereditary tyrosinaemia type 1Life Saving Drugs Program – Paroxysmal nocturnal haemoglobinuria – Initial application
3 February 2021FormTreating physicians use this application form to apply for a patient to access LSDP medication for paroxysmal nocturnal haemoglobinuria for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Paroxysmal nocturnal haemoglobinuriaLife Saving Drugs Program – Pompe disease – Initial application
3 February 2021FormTreating physicians use this application form to apply for a patient to access LSDP medication for Pompe disease for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Pompe diseaseLife Saving Drugs Program – Fabry disease – Initial application
3 February 2021FormTreating physicians use this application form to apply for a patient to access LSDP medication for Fabry disease for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Fabry diseaseLife Saving Drugs Program – Mucopolysaccharidosis type I (MPS I) – Initial application
3 February 2021FormTreating physicians use this application form to apply for a patient to access LSDP medication for MPS I for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Mucopolysaccharidosis type I (MPS I)Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Initial application
3 February 2021FormTreating physicians use this application form to apply for a patient to access LSDP medication for MPS II for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Mucopolysaccharidosis type II (MPS II)Life Saving Drugs Program – Mucopolysaccharidosis type IVA (MPS IVA) – Initial application
3 February 2021FormTreating physicians use this application form to apply for a patient to access LSDP medication for MPS IVA for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Mucopolysaccharidosis type IVA (MPS IVA)Life Saving Drugs Program – Mucopolysaccharidosis type VI (MPS VI) – Initial application
3 February 2021FormTreating physicians use this application form to apply for a patient to access LSDP medication for MPS VI for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Mucopolysaccharidosis type VI (MPS VI)Life Saving Drugs Program – Paroxysmal nocturnal haemoglobinuria – Meningococcal vaccination certificate
3 February 2021FormTreating physicians use this document to certify their patient's meningococcal vaccination status when applying or reapplying for eculizumab through the Life Saving Drugs Program.
Part of a collection: Life Saving Drugs Program resources – Paroxysmal nocturnal haemoglobinuriaLife Saving Drugs Program – Mucopolysaccharidosis type IVA (MPS IVA) – Patient test results spreadsheet
3 February 2021DatasetSpecialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.
Part of a collection: Life Saving Drugs Program resources – Mucopolysaccharidosis type IVA (MPS IVA)Life Saving Drugs Program – Mucopolysaccharidosis type VI (MPS VI) – Patient test results spreadsheet
3 February 2021DatasetSpecialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.
Part of a collection: Life Saving Drugs Program resources – Mucopolysaccharidosis type VI (MPS VI)
09 April 2021